Value
4.8/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 5.7 |
| EV/EBITDA | 2.7 |
| Fwd P/E | 7.5 |
| PEG | 4.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 16.6x
- ▸PEG: 2.52
GILD · Why this verdict
Why Gilead Sciences (GILD) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Gilead operates a high-quality franchise with 43% return on equity, best-in-class margins of 31%, and a perfect four-quarter earnings beat streak, while 14.1% upside to the analyst consensus target and a 2.4-to-1 risk/reward offer a structurally sound setup. The near-term constraint is price momentum: the stock is below its 200-day moving average in what the data characterizes as a pullback within a still-rising trend—not a confirmed breakdown—but momentum has not yet turned to support a new commitment, and 90% of revenue concentrated in three wholesale distributors is a latent vulnerability.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business earns a 43% return on equity, sustains net margins of 31%, and scores at the top tier of its peer group on quality metrics—with a near-perfect Piotroski financial health score of 8 out of 9—making it one of the more financially sound franchises in large-cap healthcare. Quality breakdown | Net margin remains above 25% and return on equity stays above 30% over the next four quarters, confirming that the margin and return profile is structural rather than cyclical. | ↓Deteriorating |
| CounterRevenue concentration in three large wholesale distributors—who together account for 90% of sales—means a renegotiation or contract loss could rapidly compress volumes and erode the margins that currently support the quality standing. | ||
The company has beaten analyst earnings estimates in each of the last four consecutive quarters, with an average surprise of nearly 7%—a track record of consistently under-promising and over-delivering that gives credibility to the forward earnings multiple of 12.9x. Catalyst breakdown | The beat streak extends to six or more consecutive quarters, keeping the average earnings surprise above 5% and sustaining confidence in forward guidance. | ↓Deteriorating |
| CounterThe dividend payout is flagged as potentially uncovered by cash flow, which could constrain future earnings reinvestment and may eventually force a payout reset that would unsettle income-oriented holders who currently price in yield. | ||
Price sits below the 200-day moving average, but that average is still rising at 2.2% per month—the data characterizes this as a pullback within an uptrend rather than a confirmed breakdown—suggesting the technical weakness may be a temporary headwind rather than a structural trend reversal. Momentum breakdown | Price recovers above the 200-day moving average within two to three months, with on-balance volume stabilizing and confirming that institutional demand has returned. | ↑Improving |
| CounterOn-balance volume is falling—indicating more shares are being sold than accumulated at current levels—and if selling continues to outpace buying, what the data treats as a temporary dip can deepen into a more sustained decline. | ||
Three large wholesale distributors together account for 90% of revenue—a level of customer concentration flagged as a high-severity concern—as any renegotiation, disintermediation, or distributor-side financial stress would directly impair a dominant share of the revenue base. Bear case | Revenue from the three major wholesale distributors remains stable or grows, and no single distributor relationship shows signs of renegotiation or volume loss over the next four quarters. | ↓Deteriorating |
| CounterThe business has sustained a 43% return on equity and best-in-class margins despite this concentration structure, suggesting the wholesale partnerships are entrenched and the risk is more theoretical than near-term operational. | ||
The business earns a 43% return on equity, sustains net margins of 31%, and scores at the top tier of its peer group on quality metrics—with a near-perfect Piotroski financial health score of 8 out of 9—making it one of the more financially sound franchises in large-cap healthcare.
↓DeterioratingQuality breakdown
- Expectation
- Net margin remains above 25% and return on equity stays above 30% over the next four quarters, confirming that the margin and return profile is structural rather than cyclical.
CounterRevenue concentration in three large wholesale distributors—who together account for 90% of sales—means a renegotiation or contract loss could rapidly compress volumes and erode the margins that currently support the quality standing.
The company has beaten analyst earnings estimates in each of the last four consecutive quarters, with an average surprise of nearly 7%—a track record of consistently under-promising and over-delivering that gives credibility to the forward earnings multiple of 12.9x.
↓DeterioratingCatalyst breakdown
- Expectation
- The beat streak extends to six or more consecutive quarters, keeping the average earnings surprise above 5% and sustaining confidence in forward guidance.
CounterThe dividend payout is flagged as potentially uncovered by cash flow, which could constrain future earnings reinvestment and may eventually force a payout reset that would unsettle income-oriented holders who currently price in yield.
Price sits below the 200-day moving average, but that average is still rising at 2.2% per month—the data characterizes this as a pullback within an uptrend rather than a confirmed breakdown—suggesting the technical weakness may be a temporary headwind rather than a structural trend reversal.
↑ImprovingMomentum breakdown
- Expectation
- Price recovers above the 200-day moving average within two to three months, with on-balance volume stabilizing and confirming that institutional demand has returned.
CounterOn-balance volume is falling—indicating more shares are being sold than accumulated at current levels—and if selling continues to outpace buying, what the data treats as a temporary dip can deepen into a more sustained decline.
Three large wholesale distributors together account for 90% of revenue—a level of customer concentration flagged as a high-severity concern—as any renegotiation, disintermediation, or distributor-side financial stress would directly impair a dominant share of the revenue base.
↓DeterioratingBear case
- Expectation
- Revenue from the three major wholesale distributors remains stable or grows, and no single distributor relationship shows signs of renegotiation or volume loss over the next four quarters.
CounterThe business has sustained a 43% return on equity and best-in-class margins despite this concentration structure, suggesting the wholesale partnerships are entrenched and the risk is more theoretical than near-term operational.
Per-dimension breakdown
Quality
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 9.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.1 |
| FCF quality | 10.0 |
| Moat | 5.1 |
| Rule of 40 | 7.2 |
| Piotroski F | 5.6 |
- ▸FCF-positive despite GAAP loss (FCF margin 34%, FCF yield 5.1%)
- ▸No competitive moat
- ▸Rule of 40: 41 (pass)
Growth
2.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.2 |
| EPS growth | 0.0 |
Momentum
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.4 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.9 |
| Analyst rating | 7.5 |
| Price target | 5.4 |
- ▸LLM news sentiment: +0.38 (n=3)
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸Insider selling (low materiality) — $19,252,399 (0.009% of mkt cap)
Peer rank
2.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.3 |
| quality rank | 0.0 |
| growth rank | 5.6 |
Technical
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.3 |
| support resistance | 2.6 |
| 52w position | 9.1 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.2 |
| days to cover | 7.3 |
| volatility | 5.2 |
| put call | 0.3 |
| implied vol | 5.9 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 3.0 |
| news risk | 4.0 |
- ▸Elevated put/call: 1.95
- ▸Above max pain $100
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 6.5 |
| dividend safety | 6.2 |
| news activity | 7.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:7.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:97d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.54
Upside
-7.3%
Downside
13.6%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 69, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 3.9 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 7.5) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.5=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.54 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 7.5, Sentiment at 6.7, and Catalyst at 6.6; the weakest are Peer rank at 2.1, Growth at 2.1, and Technical at 4.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.54 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Franchise Best In Class Margins
Trip ifNet margin compresses below 20% for 2 consecutive quarters, undermining the best-in-class profitability claim.
- P2Consistent Earnings Delivery
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the consistent beat streak.
- P3Momentum Headwind Not Confirmed Breakdown
Trip ifPrice falls more than 10% below the 200-day moving average while on-balance volume declines for 3 consecutive months, confirming a structural downtrend rather than a temporary pullback.
- P4Wholesale Concentration Revenue Risk
Trip ifRevenue from the three major wholesale distributors falls below 70% of total revenue for 2 consecutive fiscal years, indicating meaningful customer diversification has reduced concentration risk.